The synthetic ghrelin receptor agonist MK0677 increases mesolimbic/mesocortical dopamine release following local administration in the ventral tegmental area without affecting anxiety or cued fear extinction

Anouk Pierre (Speaker), Van Schuerbeek, A. (Speaker), Allaoui, W. (Speaker), Eva-Maria Fritz (Contributor), Nicolas Singewald (Contributor), tom beckers (Contributor), Van Eeckhaut, A. (Speaker), Smolders, I. (Speaker), De Bundel, D. (Speaker)

Activity: Talk or presentationTalk or presentation at a conference

Period21 May 2019
Event titleC4N day
Event typeConference